C4X Discovery Holdings PLC GRANT OF OPTIONS AND DIRECTORS DEALING (0040Q)
November 24 2016 - 2:01AM
UK Regulatory
TIDMC4XD
RNS Number : 0040Q
C4X Discovery Holdings PLC
24 November 2016
23 November 2016
C4X Discovery Holdings plc
("C4XD" or the "Company")
GRANT OF OPTIONS AND DIRECTORS DEALING
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug
discovery and development company, announces that on 23 November
2016, 1,112,037 options over ordinary shares of the Company were
awarded pursuant to the EMI 2014 Plan to certain employees,
including 300,000 options to Brad Hoy, Chief Financial Officer as
set out below.
Name Position Number Option Percentage
of share exercise of issued
options price share capital
awarded per share (%)
(pence)
---------- ----------------- ---------- ----------- ---------------
Chief Financial
Brad Hoy Officer 300,000 105p 0.8%
---------- ----------------- ---------- ----------- ---------------
The options have an exercise price of 105p being the average of
the mid-market closing price of the Ordinary Shares over the three
days prior to 23 November 2016. The options can be exercised at any
time between 3 years and 10 years of them being granted.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
---- --------------------------------------------------------------------------------------------------------------
a) Name Brad Hoy
---- ------------------------------------------------------------ ------------------------------------------------
2 Reason for the notification
---- --------------------------------------------------------------------------------------------------------------
Chief Financial Officer, Director
a) Position/status
---- ------------------------------------------------------------ ------------------------------------------------
b) Initial notification/Amendment Initial Notification
---- ------------------------------------------------------------ ------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- --------------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
---- ------------------------------------------------------------ ------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------------ ------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- --------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument options over 1p ordinary shares - EMI 2014 Plan
Identification code
ISIN GB00BQQ2RV18
---- ------------------------------------------------------------ ------------------------------------------------
b) Nature of the transaction Grant of options over ordinary shares
---- ------------------------------------------------------------ ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
---- ------------------------------------------------------------ ------------------------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
---- ------------------------------------------------------------ ------------------------------------------------
e) Date of the transaction 23 November 2016
---- ------------------------------------------------------------ ------------------------------------------------
f) Place of the transaction N/A
---- ------------------------------------------------------------ ------------------------------------------------
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Zeus Capital Limited
Dan Bate 0161 831 1512
Dominic Wilson/Phil Walker
0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4X's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4X to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUOSURNUAAUUA
(END) Dow Jones Newswires
November 24, 2016 02:01 ET (07:01 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024
